Dergiler / Neurological sciences and neurophysiology (Online) / 2020 / Cilt: 37 - Sayı: 4

Botulinum Toxin Injections for Neurological Disorders: Experience between 1994 and 2019

Sayfa
197–202
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Except for mild cosmetic complications, BoNT is generally safe in experienced hands.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: Reported results of botulinum toxin (BoNT) injections vary widely in different studies and in different neurological disorders.
📊
Temel Bulgular & Veri:The aim of this study was to investigate the efficacy and safety of BoNT injections for each neurological disorder and to report our experience in this area since 1994.
💡
Sonuç & Katkı:Except for mild cosmetic complications, BoNT is generally safe in experienced hands.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Aim: Reported results of botulinum toxin (BoNT) injections vary widely in different studies and in different neurological disorders. The aim of this study was to investigate the efficacy and safety of BoNT injections for each neurological disorder and to report our experience in this area since 1994. Materials and Methods: All patients who were injected with BoNT since 1994 were included in this retrospective study. Age, gender, etiology, specific diagnosis, time from first symptom to first injection, type of BoNT (onabotulinum toxin‑abobotulinum toxin), doses, treatment response, and complications were extracted from patient files. Etiologies were classified into five main groups: hyperkinetic movement disorders, focal spasticity, painful conditions, sialorrhea, and hyperhidrosis. Positive treatment response was defined as any objective clinical improvement determined by the attending physician and declared by the patient. Results: We determined that 1792 patients were considered for BoNT injections. Among them, 341 were not found to be suitable for injections or did not accept to have the procedure done. In total, 1451 different patients were included in the study. The most common indications for BoNT injection were hyperkinetic movement disorders (72.3%) and focal spasticity (15.2%). Other disorders included painful conditions, hyperhidrosis, and sialorrhea. In 74.3% of the patients, the only injected toxin was onabotulinum toxin, whereas 10.2% of the patients were injected only with abobotulinum toxin. In 14.7% of the patients, the injection type was changed from one to the other, due to ineffectiveness or unavailability. Response rates were 95.4% for focal spasticity, 92.6% for hyperkinetic movement disorders, 81.1% for painful conditions, 66.7% for hyperhidrosis, and 63.1% for sialorrhea. Severe complications were seen in 0.6% of the patients. Conclusion: BoNT injections seem to be effective in all of the neurological disorders which we investigated. Except for mild cosmetic complications, BoNT is generally safe in experienced hands.

🔖

Bu Makaleye Atıf Yap

BÖLÜK, C., KUTSAL, Y. G., GÜNDÜZ, A., ADATEPE, N. U., KARAALİ, F. S., KAYTAZ, A., KIZILTAN, M. E. (2020). Botulinum Toxin Injections for Neurological Disorders: Experience between 1994 and 2019. Neurological sciences and neurophysiology (Online), Cilt: 37 - Sayı: 4, 197–202. https://ajindex.com/articles/290594

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Kenney C, Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm (Vienna) 2008;115:585-91
  2. Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A. Fifteen‑year experience in treating blepharospasm with Botox or Dysport: Same toxin, two drugs. Neurotox Res 2009;15:224-31
  3. Vogt T, Lüssi F, Paul A, Urban P. Long‑term therapy of focal dystonia and facial hemispasm with botulinum toxin A. Nervenarzt 2008;79:912-7
  4. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004;75:951‑7
  5. Bakheit AM. Botulinum toxin in the management of childhood muscle spasticity: Comparison of clinical practice of 17 treatment centres. Eur J Neurol 2003;10:415-9
  6. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008;64:274-83
  7. Sürmelioğlu Ö, Dağkıran M, Tuncer Ü, Özdemir S, Tarkan Ö, Çetik F, et al. The Effectiveness of botulinum toxin Type A injections in the management of Sialorrhea. Turk Arch Otorhinolaryngol 2018;56:111-3
  8. Ramirez‑Castaneda J, Jankovic J. Long‑term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel) 2013;5:249-66
  9. Ababneh OH, Cetinkaya A, Kulwin DR. Long‑term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol 2014;42:254‑61
  10. Safarpour Y, Jabbari B. Botulinum toxin treatment of movement disorders. Curr Treat Options Neurol 2018;20:4
  11. Mclellan K, Das RE, Ekong TA, Sesardic D. Therapeutic botulinum type A toxin: Factors affecting potency. Toxicon 1996;34:975-85
  12. Francisco GE. Botulinum toxin for post‑stroke spastic hypertonia: A review of its efficacy and application in clinical practice. Ann Acad Med Singapore 2007;36:22-30. 13. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. PLoS medicine 2007;4(10):e296
  13. Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O. Long‑term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002;17:1288-93
  14. Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotox Res 2006;9:145‑8
  15. Naumann M, Jankovic J. Safety of botulinum toxin type A: A systematic review and meta‑analysis. Curr